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Abstract
Background: Twelve percent of births in the United States occur before 37 weeks of
gestation and therefore are considered preterm births (Norwitz, 2015). While the ability
to identify women at risk for preterm birth has improved dramatically over the past three
decades, the application of primary and secondary interventions has failed to reduce the
incidence of preterm delivery, which has actually been on the rise (Norwitz, 2015).
Preterm birth is a phenomenon that needs to be reduced not only in the United States, but
also across the world.
Purpose: To determine to what extent the use of supplemental progesterone in pregnancy
can aid in preventing preterm labor, and more importantly preterm birth, in women who
are at a high-risk for preterm birth.
Results: Twenty articles were identified for review and appraised using the John Hopkins
Research Evidence Appraisal Tool. The major findings of the reviewed literature
concluded that the use of progestational agents is an effective measure in preventing
preterm birth and improving neonatal outcomes.
Conclusion: By reducing the rate of preterm birth, there is potential to reduce many other
linked outcomes such as neonatal outcomes and costs related to premature delivery
complications. Progestational agents are an effective measure in preventing preterm birth
in high-risk women. Screening women for preterm birth risk factors early in their
antenatal care is an appropriate primary prevention technique. The use of progestational
agents in high-risk women is an appropriate secondary prevention technique that has
shown many benefits.
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Implications for Research and Practice: There is a need for further research focusing
specifically on multiple gestation pregnancies and pregnancies with known fetal
anomalies and the use of progestational agents. Significant research has focused on
singleton gestation pregnancies and pregnancies with known fetal anomalies excluded
from these research studies. Additionally, further research needs to be conducted on
optimal administration route, timing of administration, and studies investigating costeffectiveness.
Keywords: progesterone, preterm birth, pregnancy, preterm labor, prevention, and short
cervix.
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Chapter I: Introduction
Preterm birth is defined as the ‘delivery of an infant between 20 and 37 weeks of
gestation and is the greatest contributor to infant death and a leading cause of long-term
neurological disabilities in children (Centers for Disease Control and Prevention, 2015;
The American Congress of Obstetricians and Gynecologists, 2015). The risk of mortality
and morbidity strongly correlates with birth weight and the gestational age at the time of
delivery with the highest risk being early gestational age (Mackenzie, Walker, Armson,
& Hannah, 2006). In addition to the potential health consequences of preterm birth, the
cost of premature infants needing the neonatal intensive care unit (NICU) or long-term
care is enormous and overwhelming (Mackenzie, Walker, Armson, & Hannah, 2006).
Unfortunately, the reality is that twelve percent of births in the United States occur before
37 weeks of gestation and therefore are considered preterm births (Norwitz, 2015).
Preterm birth is a phenomenon that needs to be reduced not only in the United States, but
across the world.
Throughout history, researchers and providers have focused on active
management (tertiary prevention) of preterm labor (regular contractions of the uterus
resulting in cervical change that start before 37 weeks of pregnancy) in preventing
preterm birth (ACOG, 2015). These efforts to delay delivery in women presenting with
acute preterm labor have been largely unsuccessful (Norwitz, 2015). While the ability to
identify women at risk for preterm birth has improved dramatically over the past three
decades, the application of primary and secondary interventions has failed to reduce the
incidence of preterm delivery, which has actually been on the rise (Norwitz, 2015).
Statement of Purpose
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The intent of this critical appraisal of the literature is to determine to what extent
the use of supplemental progesterone in pregnancy can aid in preventing preterm labor,
and more importantly preterm birth, in women who are at a high-risk for preterm birth.
By developing an evidenced-based method for primary prevention of preterm labor and
birth, maternal and neonatal outcomes have the potential to improve exponentially.
Need for Critical Review of a Nurse-Midwifery Problem
Healthy People has developed a set of science-based, 10-year national objectives
for improving the health of all Americans (Office of Disease Prevention and Health
Promotion, 2016). A vast majority of these objectives focus on maternal, infant, and child
health. Pertinent Healthy People 2020 objectives include MICH-1 reduce the rate of fetal
and infant deaths, MICH-8 reduce low birth weight (LBW) and very low birth weight
(VLBW), and finally, MICH-9 reduce preterm births (ODPHP, 2016). Developing a
research-supported method to aid in primary and secondary prevention of preterm birth
would contribute to the success of these Healthy People 2020 goals and improve maternal
and neonatal outcomes not only nationally, but worldwide.
The first randomized controlled trial of progestational agents for the prevention of
preterm birth in high-risk women was published in 1970 by Paperink (Mackenzie,
Walker, Armson, & Hannah, 2006). The evidence on the use of supplemental
progesterone in preventing preterm labor and preterm birth is a relatively new
phenomenon in medicine that has been identified as a mechanism to potentially reduce
the risk of spontaneous preterm birth in a variety of high-risk populations (Norwitz,
2015). While supplemental progesterone is currently used in medical practice in an effort
to reduce the incidence of preterm birth, there is a significant disconnect in the
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appropriate timing, route, and dose of treatment. Over the past decade, there have been
numerous research studies to attempt to identify these factors and a critical review of the
literature is needed to analyze the data as a whole and determine the most appropriate
treatment plan, if any.
Significance to Nurse-Midwifery
Nurse-midwives are on the forefront for providing exceptional prenatal care and
identifying women at risk for pregnancy complications. At every visit, especially the first
visit, the nurse-midwife is assessing the women’s history and clinical picture. Identifying
women at risk for certain complications such as preterm birth is crucial. If a nursemidwife is able to prevent even one preterm birth, he/she is potentially saving a life. The
art and science of nurse-midwifery are characterized by hallmarks including
incorporation of scientific evidence into clinical practice, health promotion, disease
prevention, and health education, and care to vulnerable populations- to name a few
(American College of Nurse-Midwives, 2012). By understanding the potential impact of
supplemental progesterone therapy, nurse-midwives will better serve these hallmarks of
nurse-midwifery and the patients that may benefit from secondary intervention.
Conceptual Model
The conceptual model selected for this critical appraisal is Betty Neuman’s
Systems Model (Petiprin, 2015). A systems perspective requires the nurse-midwife to not
only view the interaction of the subsystems within the system but also the effect that each
subsystem on the other subsystems (Reed, 1993). In other words, the Systems Model
focuses on the response of the patient system to stressors and the use of primary,
secondary, and tertiary nursing prevention, intervention, attainment, and maintenance of
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patient system wellness (Petiprin, 2015). This model is applicable to primary, secondary,
and tertiary prevention of preterm birth and the potential effects that progesterone has on
patient system wellness.
The Neuman’s Systems Model has basic beliefs, called assumptions, which are
necessary to understand when using the Neuman Model. The following assumptions are
found in the Neuman model (Neuman, 1989, pp. 21-22, 77; Reed, 1993 pp. 5-7).
1. Though each individual client or group as a client system is unique, each
system is a composite of common known factors or innate characteristics
within a normal, given range of response contained within a basic
structure.
2. Many, known, unknown, and universal and environmental stressors exist.
Each differs in its potential for disturbing a client’s usual stability level, or
normal line of defense. The particular interrelationships of client variables
- physiological, psychological, sociocultural, developmental, and spiritual
- at any point in time can affect the degree to which a client is protected by
flexible line of defense against possible reaction to a single stressor or
combination of stressors.
3. Each individual client/client system, over time, has evolved a normal
range of response to the environment that is referred to as a normal line of
defense, or usual wellness/stability state.
4. When the cushioning, accordion-like effect of the flexible line of defense
is no longer capable of protecting the client/client system against an
environmental stressor, the stressor breaks through the normal line of
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defense. The interrelationships of variables - physiological, psychological,
sociocultural, developmental, and spiritual - determine the nature and
degree of the system reaction or possible reaction to the stressor invasion.
5. The client, whether in a state of wellness or illness, is a dynamic
composite of the interrelationships of variables - physiological,
psychological, sociocultural, developmental, and spiritual. Wellness is on
a continuum of available energy to support the system in its optimal state.
6. Implicit within each client system is a set of internal resistance factors,
known as lines of resistance (resources), which function to stabilize and
return the client to the usual wellness state (normal line of defense) or
possible to a higher level of stability following an environmental stressor
reaction.
7. Primary prevention relates to general knowledge that is applied in client
assessment and intervention in identification and reduction or mitigation
of risk factors associated with environmental stressors to prevent possible
stressor reaction.
8. Secondary prevention relates to symptomatology following a reaction to
stressors appropriate ranking of intervention priorities, and treatment to
reduce their noxious effects.
9. Tertiary prevention relates to the adjustive processes taking place as
reconstitution begins and maintenance factors move the client back in a
circular manner toward primary prevention.
10. The client is in dynamic constant energy exchange with the environment.
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Figure 1.1 depicts Neuman’s Systems Model. The circle surrounded by the series
of concentric rings graphically represents the client. The rings are known as the basic
structure and serve as a protective structure for the client and to help maintain a stable
state (Reed, 1993). The outer ring is known as the flexible line of defense (FLD) and is
the outer boundary of the client that protects the normal line of defense or usual state of
wellness of the client (Reed, 1993). The FLD is ultimately the first line of defense in
response to stressors from the environment (Reed, 1993). An example of a stressor in
regards to the research question may be a history of preterm birth or a sonographically
short cervix. The next ring is known as the normal line of defense (NLD) and represents
the client’s usual state of wellness (Reed, 1993). And finally, lines of resistance (LR) are
the closest mechanism and function as a protectant for the basic structure’s integrity
(Reed, 1993). When these lines of defense and resistance are effective, the system is able
to reconstitute and return to a steady state and when they are ineffective, death or illness
of the system may occur (Reed, 1993).
Physiological, psychological, sociocultural, developmental, and spiritual variables
have an influence on the system (Reed, 1993). Another positive or negative influence on
the system includes both internal and external environmental stress factors (Reed, 1993).
These environmental factors are further divided into internal, external, and created.
The internal environment (intrapersonal) “consists of all forces or interactive
influences internal to or contained solely within boundaries of the client” (Neuman, 1989,
pp. 31; Reed, 1993, pp. 11). This forms as the result of relationships among the
subsystems of the client (Reed, 1993). The external environment consists of intrapersonal
or extrapersonal influences (Reed, 1993). These influences include interaction of the
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client with another person such as a work colleague, family member, or healthcare team
member (Reed, 1993). The created environment is the client’s attempt to create a safe
setting for functioning (Reed, 1993). In particular, this created environment is developed
by the client if the client perceives a threat to the basic structure and function of the
system (Reed, 1993).
In every environment, there are stressors that have the potential to cause
disequilibrium. These stressors can be divided into intrapersonal, interpersonal, and
extrapersonal stressors. The stressor’s effect on the client is dependent on the strength of
the stressor, the number of stressors present at any given time, and the ability of the client
to protect against the stressor (Reed, 1993). In the Neuman Model, health and wellness
are considered the same (Reed, 1993). Wellness occurs when system needs are fully met
and the client is healthy. Obviously, the reverse is true as well - when there are unmet
needs, wellness is reduced.
The nursing goal is to keep the client well and stable by integrating appropriate
interventions (Reed, 1993). There are three levels of prevention used to attain, maintain
and retain wellness - primary, secondary, and tertiary (Reed, 1993). Primary prevention is
aimed at decreasing risk factors and increasing the FLD’s ability to withstand
environmental stressors (Reed, 1993). Secondary prevention comes into effect when the
NLD is disrupted. It is aimed at strengthening at protecting the basic structure and
strengthening the LR (Reed, 1993). Tertiary prevention focuses on helping treating the
client in order to promote a healthy return to a wellness state (Reed, 1993).
Until recently, preterm birth has largely focused on the tertiary level of prevention
to delay delivery in women presenting with acute preterm labor (Norwitz, 2015). The
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rates of preterm labor, preterm birth, and complications in relation to these factors result
in suffering. Women may be at risk for preterm birth if they have a personal history of
previous spontaneous preterm birth or have a sonographically identified short cervix. By
identifying women at risk for preterm birth early in their pregnancies, nurse-midwives
will be utilizing primary prevention and by determining and implementing the safest
method of progesterone supplementation in high-risk women in an effort to avoid preterm
birth nurse-midwives will be encompassing secondary prevention. By acting upon these
assessments, the provider will have a better chance of being successful in keeping the
client and the fetus in a state of wellness and health. Prevention as intervention is the
basis of health promotion and needs to encompass primary, secondary, and tertiary
prevention in order to be successful.
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Figure 1.1: Neuman’s Systems Model Diagram

(Harris County District Hospital, n.d.)
Summary
As healthcare, midwifery, and medicine continue to evolve, we must make a
cognizant effort to remain up-to-date on current research. The use of progesterone
supplementation in pregnant women with a high-risk for preterm birth is growing. There
is evidence supporting the use of progesterone; however, there is still inconsistent
information on the preferred route, dosing, diagnostic criteria and timing of
administration. This chapter described the consequences of preterm labor and birth and
the need for primary and secondary prevention strategies, the need for a critical review of
the literature, the significant to nurse-midwifery, and the conceptual model supporting the
review.
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Chapter 2 describes the strategies used for appraisal of the literature including
databases, search terms, inclusion and exclusion criteria, a summary of the number and
types of research selected for this critical review, and criteria for evaluating research
studies. Chapter 3 provides a breakdown of the review and analysis of the evidence and
includes a synthesis of major findings in the form of a matrix as well as strengths and
weakness of the research studies. Chapter 4 concludes with a synthesis of the literature
answering the research question, current trends, and gaps in the literature, implications
for nurse-midwifery, recommendations for further nursing research, and application and
integration of the identified conceptual model.
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Chapter II: Methods
This chapter will discuss the search methods used in this critical appraisal of the
literature. Studies related to the prevention of preterm birth in high-risk women by
utilizing the use of progesterone were included. This chapter describes the search
strategies to identify research studies that answer the research question, strategies used to
evaluate the research, explanation of inclusion and exclusion criteria, and the number and
types of studies found in the literature review. Finally, the evaluation process for
determining the level and quality of the evidence in the research studies will be
explained.
Search Strategies Used to Identify Research Studies
The purpose of this critical appraisal of the literature is to determine if the use of
progesterone in high-risk singleton pregnancies reduces the risk of preterm labor and
birth. An initial search was conducted utilizing a basic general search of several EBSCO
databases with scholarly articles including Academic Search Premier, AgeLine, Alt
HealthWatch, Database of Abstracts of Reviews of Effects, EBSCO MegaFILE, ERIC,
Family & Society Studies Worldwide, GreenFILE, MasterFILE Premier, MLA
International Bibliography, Music Index, New Testament Abstracts, Old Testament
Abstracts, Philosopher's Index, Professional Development Collection, PsycINFO,
Teacher Reference Center, and Business Source Premier through the Bethel University
library using a combination of the following key words: progesterone, preterm birth,
pregnancy, preterm labor, progesterone, prophylactic progesterone, prevention, high-risk,
premature, early labor, and short cervix.
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Strategies Used to Evaluate the Research
The John Hopkins Nursing Evidence-Based Practice: Model and Guidelines by
Deerholt & Dang (2012) were used to evaluate the research studies in this critical
appraisal of the literature. The John Hopkins Research Evidence Appraisal Tool allowed
the research studies to be critiqued based on the level and quality of the evidence
(Deerholt & Dang, 2012). The evidence was categorized from level I-IV according to the
John Hopkins Research Evidence Appraisal Tool (Deerholt & Dang, 2012). Level I
research studies include experimental studies that are randomized controlled trials (RCT),
and systematic reviews of RCTs with or without a meta-analysis. Level II research
studies include quasi-experimental studies and systemic reviews that include RCTs and
quasi-experimental studies with or without meta-analysis. Level III research studies are
non-experimental studies, qualitative studies, or a combination of RCTs, quasiexperimental and non-experimental studies with or without meta-analysis. Level IV
studies include opinions of respected authorities, clinical practice guidelines, or expert
committee/consensus panels based on scientific evidence (Deerholt & Dang, 2012).
Research studies are considered ‘high quality’ if the results obtained are
generalizable, have a sufficient sample size, design, adequate control, and definitive
conclusions. If the study has reasonably consistent results, a sufficient sample size,
design, moderate control, and fairly definitive conclusions, it is then considered ‘good
quality’. And finally, research studies are categorized as ‘low quality’ if there is little
evidence with inconsistent results, insufficient sample size for the study, and if
conclusions are unable to be drawn from the results (Deerholt & Dang, 2012). The
studies were further analyzed based on their purpose, sample, design, measurement,
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results, conclusions, and recommendations. The data were then organized in the form of a
Matrix (Table 1).
Criteria for Including or Excluding Research Studies
Experimental, quasi-experimental, and non-experimental research studies of all
qualities were included in the matrix. Many of the studies in the initial search were
excluded because their content did not relate to the purpose of the review or pertain to the
research question. All ages, routes of medication administration, formulations, and timing
of medication administration were included. Singleton pregnancies were included and
multi-gestation pregnancies were omitted for the sake of data analysis but if the study
included data on singleton pregnancies as well, it was included. Only studies written in
English were included.
Number and Types of Studies Selected for the Review
A total of 748 studies were evaluated in the initial selection. Abstracts were
reviewed and many studies that did not pertain to the research question were immediately
omitted. The remaining studies were organized according to original research, literature
review, meta-analysis, and expert opinion. The studies were also sorted according to the
type of research. In addition, the references within the research studies were analyzed
yielding additional pertinent literature for review.
Ultimately, 20 articles were chosen for the final review and compiled into
matrices. 10 of these studies were ‘high quality’ and 10 of these studies were ‘good
quality’. Table 1 summarizes the studies that were included in the final review in an
organized matter. The matrix was developed using the headings: citation, purpose,
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sample, design, measurement, results/conclusions, recommendations, and level/quality.
The matrix was then sorted alphabetically by author.
Summary
The use of progesterone for preterm birth prophylaxis in high-risk mothers is not
well understood in terms of route, timing, appropriate use, and duration of use which,
presented a need for a critical appraisal of the literature. There is a need for analysis of
the evidence to determine these items as well as analyze neonatal outcomes. The Matrix
(table 1) includes 20 studies that provide a thorough evaluation of the evidence. This
chapter summarized the search and evaluation strategies used for this critical appraisal of
the literature.
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Chapter III: Literature and Analysis
Chapter Three synthesizes the major findings of the literature review as it pertains
to the use of progesterone to prevent preterm birth. Strengths and weaknesses of the
selected research studies will be discussed. The articles are organized in a matrix, which
has been alphabetized by author for ease of use for the reader.
Synthesis of Matrix
The matrix was created as a tool to organize the selected research studies.
Organization in this manner allows for an easier identification of trends in the research
studies. Twenty studies were selected for the final matrix. The following headings were
utilized in every matrix entry: citation, purpose, sample, design, measurement,
results/conclusions, recommendations, and level/quality. After organizing and examining
the studies, the findings were synthesized and implications for practice were identified.
Synthesis of Major Findings
Effectiveness of Placebo and Progestational Agents
One of the most important measures of the critical appraisal was to determine if
the use of progestational agents was effective in preventing preterm birth. In the studies
identified for review, researchers often determined effectiveness by comparing
effectiveness of progestational agents with placebo agents.
The research for this review that investigated the effectiveness of progestational
agents dated back until 2003. There were two research articles published in 2003 that
were included in this literature review. The first study by Meis et al. (2003) provided
statistically significant results that treatment with progestational agents significantly
reduced the risk of delivery at less than 37 weeks of gestation (incidence, 36.3% in the
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progesterone group vs. 54.9% in the placebo group; relative risk, 0.66 [95% confidence
interval, 0.54 to 0.81]), 35 weeks of gestation (incidence, 20.6% vs. 30.7%; relative risk,
0.67 [95% confidence interval, 0.48 to 0.93]), and 32 weeks of gestation (11.4% vs.
19.6%; relative risk, 0.58 [95% confidence interval, 0.37 to 0.91]). This was further
confirmed by a second study in 2003 by Da Fonesca, Bittar, Carvalho, and Zugaib in
which a placebo and progestational agents were utilized in 142 cases. In this study, 72
women received progesterone and 70 received a placebo (Da Fonesca et al., 2003). Of
the 142 cases in the study, there were a total of 30 preterm births or a preterm birth rate of
21.1% (Da Fonesca et al., 2003). The study concluded that there were differences in
uterine activity between the progesterone and placebo (23.6% vs. 54.3%, respectively; p
< .05). and in preterm birth rates between the progesterone and placebo groups (13.8%
vs. 28.5%, respectively; p < .05) as more women were delivered before 34 weeks in the
placebo group than in the progesterone group (Da Fonesca et al., 2003). Once again, the
use of progestational agents was supported by this study.
Moving forward in time, a study by Sanchez-Ramos, Kaunitz, and Delke (2005)
also compared patients who received a placebo agent to women who received
progestational agents. This study found that the women who received progestational
agents had lower rates of preterm delivery (Sanchez-Ramos, Kaunitz, & Delke, 2005).
This was confirmed in additional studies by Dodd, Crowther, Cincotta, Flenady, and
Robinson (2005) Mackenzie, Walker, Armson, and Hannah (2006). Both studies resulted
in similar outcomes of a significant reduction in delivery at less than 37 weeks with the
use of progestational agents. Once again, the research findings were supported by
Fonesca, Celik, Parra, Singh, and Nicolaides (2007) when their study suggested that
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spontaneous delivery before 34 weeks of gestation was less frequent in their progesterone
group in comparison to the placebo group.
As the research progressed throughout the years, results remained quite consistent
supporting the use of progestational agents in preventing preterm birth. Cetingoz, Cam,
Sakalli, Karateke, Celik, and Sancak (2011) determined that there was once again a
statistically significant difference in the rate of preterm birth between the placebo and
progesterone groups. More women delivered before 37 weeks of gestation in the placebo
group than in the progesterone group, therefore supporting the use of progestational
agents (Cetingoz et al., 2011). The use of progesterone also resulted in a reduction in the
preterm births before 34 weeks of gestation (Cetingoz et a., 2011).
A large study by Hassan et al. (2011) compared vaginal progesterone gel with a
placebo agent. The results revealed that women allocated to receive vaginal gel
progesterone without a history of preterm birth had a lower rate of preterm birth before
35, 33, and 28 weeks than did those allocated to placebo group (Hassan et al., 2011).
However, it is important to note that the reduction in the rate of preterm birth in women
with a prior history of preterm birth between 20 and 35 weeks of gestation did not reach
statistical significance (Hassan et al., 2011). Ultimately, the administration of vaginal
progesterone gel to women with a sonographic short cervix in the mid-trimester was
found to be associated with a 45% reduction in the rate of preterm birth before 33 weeks
of gestation (Hassan et al., 2011). And finally, in a study by Conde-Agudelo et al. (2013),
direct comparison results determined that both vaginal progesterone and cerclage were
associated with significant reductions in the risk of pre-term birth at less than 32 weeks of
gestation compared to placebo/no cerclage (relative risk 0.47, 95% confidence interval
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0.24 to 0.91, four RCTs for vaginal progesterone compared with placebo; relative risk
0.66, 95% confidence interval 0.48 to 0.91, five RCTs for cerclage compared with no
cerclage).
There were only a few articles that did not fully support the use of progestational
agents in preventing preterm birth. The first study was completed by O’Brien el al.
(2007), which determined that the use of progesterone did not decrease the frequency of
preterm birth at less than or equal to 32 weeks of gestation. Berghella et al. (2010)
conducted a second study, which determined that in 300 women, progestational agents
had no effect on preterm birth at less than 35 weeks of gestation in women with (p =
0.64) or without cerclage (p = 0.51). However, this study did conclude that preterm birth
at less than 24 weeks of gestation (odds ratio, 0.08) was significantly lower for those with
progestational agents and no cerclage (Berghella et al., 2010).
Route of Administration
Determining the optimal route for progesterone administration is important.
Currently, there are vaginal, oral, and intramuscular routes of progesterone agent
administration. Two studies from the identified studies investigated the optimal route of
progesterone administration. In terms of identifying the optimal route of administration, it
is important to take into consideration effectiveness and adverse effects.
Velez Edwards et al. (2013) performed a systemic review and meta-analysis by
drug route of 27 randomized trials. Across all of the studies analyzed, all routes (oral,
vaginal, and intramuscular) were identified as effective in reducing preterm birth in
singleton pregnancies (Intramuscular risk ratio 0.77, 95% Bayesian credible interval:
0.69-0.87; vaginal risk ratio 0.80, 95% Bayesian credible interval: 0.69-0.91; oral risk
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ratio 0.66, 95% Bayesian credible interval: 0.47-0.84) (Velez Edwards et al., 2013).
Vaginal and intramuscular progesterone were both effective in reducing neonatal deaths
in singleton pregnancies (Velez Edwards et al., 2013). This study suggests that the oral
route is not the optimal route of administration.
Maher, Abelaziz, Ellaithy, and Bazeed (2013) completed a randomized trial to
analyze the use of vaginal and intramuscular progesterone. This study revealed that
vaginal progesterone was associated with a lower percentage of deliveries before 34
weeks in comparison to the intramuscular route of administration (p = 0.02) (Maher et al.,
2013). The same outcome was seen when deliveries between 28 and 32 weeks of
gestation were analyzed (p = 0.04) (Maher et al., 2013). As far as deliveries at other
gestational ages, there were no statistically significant differences between the routes of
delivery (Maher et al., 2013).
In the study by Maher et al. (2013), adverse effects were reported higher in the
intramuscular group than the vaginal group. In their study, 14.1% of patients in the
intramuscular group reported adverse effects compared to only 7.5% in the vaginal group
(p = 0.017) (Maher et al., 2013).
Cost-Effectiveness
An important consideration to address regarding the use of progesterone for
preventing preterm birth is determining whether this strategy promotes cost-effectiveness.
Two of the studies reviewed identified cost-effectiveness as an outcome measure. It must
be determined what the appropriate screening technique is and when progesterone should
be initiated to be most effective and cost-effective.

27

Cahill et al. (2010) identified that universal sonographic screening for cervical
length and treatment with vaginal progesterone was the most cost-effective strategy and
was the best choice among three alternatives. The three alternatives were cervical length
screening for women at increased risk for preterm birth and treatment with vaginal
progesterone, risk-based treatment with 17-OHP-C without screening, and no screening
or treatment (Cahill et al., 2010). Universal screening represented savings of $1339
($8323 vs $9664), when compared with treatment with 17-OHP-C, and led to a reduction
of 95,920 preterm births annually in the United States (Cahill et al., 2010).
Pizzi, Seligman, Baxter, Jutkowitz, and Berghella (2014) analyzed a well-known
trial known as the PREGNANT trial for the cost effectiveness of the use of vaginal
progesterone 8% gel in reducing the likelihood of preterm birth among women with a
short cervix. Researches analyzed the costs and cost effectiveness of vaginal progesterone
gel versus placebo. The estimated cost per mother was US $23,079 for vaginal
progesterone gel and US $36,436 for the placebo (Pizzi et al., 2014). The costeffectiveness model showed a savings of US $24,071 per preterm birth averted with
vaginal progesterone gel (Pizzi et al., 2014). As you can see, vaginal progesterone gel
realized cost savings and cost effectiveness in 79% of simulations (Pizzi et al., 2014).
According to Petrini et al. (2005), if all eligible women receive progestational
preventative therapy, 9,870 preterm births may have been prevented, which is an
astonishing amount and would have a significant reduction in costs. If the progestational
agent were restricted to women with a history of a previous spontaneous very preterm
birth, 2,163 preterm births may have been prevented (Petrini et al., 2005).
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Effect on the Neonatal Outcomes
It is well-known that preterm birth has an effect on a neonate. There are often
higher rates of neonatal death, neonatal complications, NICU admissions, and lower birth
weights to neonates born at earlier gestations or prematurely. Because of this, it is
important to analyze if the use of progesterone not only prevents preterm birth but if there
is also an effect on neonatal outcomes. There was an overwhelming amount of research
on this; in the critical appraisal, numerous studies that addressed neonatal outcomes were
located.
The use of progestational agents to prevent preterm birth was found to be
statistically associated with decreased neonatal morbidity (Sotiriadis, Papatheodorou &
Markydimas, 2012; Fonesca et al., 2007; Rai et al. 2009), perinatal death (Berghella et
al., 2010; Rode et al., 2009), respiratory distress syndrome (Rode et al., 2009; Hassan et
al., 2011), necrotizing enterocolitis (Rode et al., 2009; Meis et al., 2003), intraventricular
hemorrhage (Dodd et al., 2005; Meis et al., 2003), need for supplemental oxygen (Meis et
al., 2003), neonatal intensive care unit (NICU) admissions (Sotiriadis, Papatheodorou &
Markydimas, 2012), NICU length of stay (Rai et al., 2009) and higher APGAR scores
(Rai et al., 2009).
One factor that has a significantly associated with some of these complications is
the infant’s weight at birth. If progestational agents have the potential to decrease the rate
of premature births, the average birth weight is likely to rise. There is a statistically
significant reduction of infants born with low birth weights when receiving progestational
agents (Sanchez- Ramos, Kaunitz, & Delke, 2005; Tita & Rouse, 2009; Dodd et al.,
2005; Rai et al., 2009; Hassan et al., 2011).
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Some studies however did not have statistically significant results between the
progestational group and the placebo groups. Rode et al. (2009) concluded that the risk of
admission for preterm labor, antenatal corticosteroid therapy, and tocolytic therapy is not
decreased in women who are treated prophylactically with progesterone. Sanchez-Ramos,
Kaunitz, and Delke (2005) had similar results in that there were no differences in rates of
hospital admissions for threatened preterm labor or perinatal mortality. Some studies
determined that there was no difference between the groups in infant morbidity or
mortality rates or other maternal or neonatal outcome measures (O’Brien et al., 2007;
Mackenzie et al., 2006; Cetingoz et al., 2011).
Strengths and Weaknesses
The strengths and weaknesses of the articles selected for the critical appraisal of
the literature were evaluated using the Johns Hopkins Research Evidence Appraisal Tool
(Dearholt & Dang, 2012). Only evidence graded ‘high’ or ‘good’ according to the
Quality Rating Scheme for Evidence as described in Dearholt and Dang (2012) was
included in the critical appraisal. There were 16 level I studies, one level II study, and
three level III studies included in the critical appraisal. Weaknesses include occasionally
less than ideal sample sizes and the need for further research in larger studies including
diverse populations and high-risk populations. An additional weakness with this critical
appraisal is that only two studies were identified that addressed the route of
administration of progestational agents. Additional studies on route of administration
would have strengthened the critical review.
Summary
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The matrix consists of 20 critically appraised articles that examine the use of
progestational agents in preventing preterm birth. Cost effectiveness, route, and neonatal
outcomes were also evaluated. The John Hopkins Research Evidence Appraisal Tool was
used to appraise the quality and evidence level of every article included in the matrix. All
of the articles met established criteria for ‘high’ or ‘good’ quality literature. Limitations,
strengths, and implications for practice were identified within the matrix. A major focus
of the appraised literature is the use of progestational agents in preventing preterm birth.
Although a few studies found no differences in the use of progestational agents in
preventing preterm birth, the majority of studies showed that this method was indeed
effective in this outcome. The use of progestational agents in high-risk women is
secondary prevention that is cost effective and improves neonatal outcomes. There is
need for further research focusing specifically on the appropriate conditions of use and
route.

Chapter IV: Discussion
This chapter is based on a discussion of the critical appraisal of the literature.
Current trends, gaps, future research topics, and application and integration of the
theoretical framework will be discussed. This discussion is based on the original research
question addressed: to what extent can the use of supplemental progesterone in pregnancy
aid in preventing preterm labor, and more importantly preterm birth, in women who are at
a high-risk for preterm birth? The John Hopkins Research Evidence Appraisal Tool was
used to appraise 20 scholarly articles related to this topic. The findings were then
evaluated and synthesized to identify trends and gaps in the literature and identify
implications for changes as well as future research topics. Betty Neuman’s Systems
Model was applied to the concept of screening women for their risk of preterm labor and
birth and implementing a preventative measure such as progesterone when appropriate.
Effectiveness of Placebo and Progestational Agents
The use of progestational agents has been recognized as an appropriate method in
preventing preterm birth in women with a history of preterm birth or have an identified
sonographic short cervix. Multiple studies included in the matrix are supportive of the use
of progestational agents in preventing preterm birth and found a significant decrease in
births at less than 37 weeks of gestation. In fact, the only two studies that lacked evidence
to support the use of progestational agents were the studies by O’Brien el al. (2007) and
Berghella et al. (2010). The repetitive findings supportive of progestational agents were
reviewed in multiple Level I studies of good or high quality based on the John Hopkins
Research Evidence Appraisal Tool. The consistency present in these results provides
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evidence and support for the use of progestational agents in preventing preterm labor and
birth in high-risk women.
It does need to be recognized that multiple gestation pregnancies and documented
known fetal anomalies were not included in this critical appraisal. It also needs to be
noted that many of the studies used different gestational ages in their outcome measures
making conclusions more difficult to generalize in this critical appraisal.
The studies by O’Brien el al. (2007) and Berghella et al. (2010) that did not show
significant evidence to support the use of progestational agents in preventing preterm
birth were both Level I studies. Although the quality of evidence was rated as good
through the Johns Hopkins Research Evidence Appraisal Tool, the lack of additional
research supporting similar and consistent results weakens the argument of implementing
a change in practice based on these two studies alone. Instead, the overwhelming amount
of evidence supporting the use of progestational agents is apparent and practice changes
would better be supported from these reproducible studies.
Route of Administration
Unfortunately, only two studies identified in this critical appraisal investigated the
optimal route of progesterone administration making it difficult to identify trends. Velez
Edwards et al. (2013) found that vaginal and intramuscular progesterone were both
effective in reducing neonatal deaths in singleton pregnancies (Velez Edwards et al.,
2013). And most importantly, this study suggests that the oral route is not the optimal
route of administration (Velez Edwards et al., 2013). This leaves the potential optimal
route choice of delivery between intramuscular and vaginal routes.
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Maher, Abelaziz, Ellaithy, and Bazeed (2013) completed a randomized trial to
analyze the use of vaginal and intramuscular progesterone. This study revealed that
vaginal progesterone was associated with a lower percentage of deliveries before 28, 32,
and 34 weeks of gestation than the intramuscular route of administration (Maher et al.,
2013). This study also identified that there are more adverse effects reported in the
intramuscular group in comparison to the vaginal group (Maher et al., 2013). This
suggests that the vaginal route may be the preferred route.
Despite the results of these two studies, there are significant gaps in research
given that there are only two studies investigating administration routes. Although the
quality of evidence was rated as good through the Johns Hopkins Research Evidence
Appraisal Tool, the lack of additional research supporting similar and consistent results
weakens the argument of implementing a change in practice based on these two studies
alone
Cost-Effectiveness
Only three of the studies reviewed identified cost-effectiveness as an outcome
measure making it difficult to identify significant trends in the literature. Cahill et al.
(2010) identified that universal sonographic screening for cervical length and treatment
with vaginal progesterone was the most cost-effective strategy and was the best choice as
opposed to cervical length screening for women at increased risk for preterm birth and
treatment with vaginal progesterone, risk-based treatment with 17-OHP-C without
screening, and no screening or treatment (Cahill et al., 2010). Universal screening
represented savings of $1,339, when compared with treatment with 17-OHP-C, and led to
a reduction of 95,920 preterm births annually in the United States (Cahill et al., 2010).
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Additionally, Pizzi, Seligman, Baxter, Jutkowitz, and Berghella (2014) analyzed a wellknown trial known as the PREGNANT trial for the cost effectiveness of the use of
vaginal progesterone 8% gel in reducing the likelihood of preterm birth among women
with a short cervix. The cost-effectiveness model showed a significant savings of US
$24,071 per preterm birth averted with vaginal progesterone gel (Pizzi et al., 2014).
According to Petrini et al. (2005), if all eligible women receive progestational
preventative therapy, 9,870 preterm births may have been prevented, which is an
astonishing amount and in turn would have a significant reduction in costs. If the
progestational agent were restricted to women with a history of a previous spontaneous
very preterm birth, only 2,163 preterm births may have been prevented (Petrini et al.,
2005).
Despite the results of these three studies, there are significant gaps in research
given that there are only three studies investigating administration routes. The quality of
evidence was rated as high and good through the Johns Hopkins Research Evidence
Appraisal Tool. However, the studies by Cahill et al. (2010) and Petrini et al. (2005) were
identified as Level III studies leaving Pizzi et al. (2014) as the only Level I study
addressing this outcome. The lack of Level I studies and additional research supporting
similar and consistent results weakens the argument of implementing a change in practice
based on these three studies alone.
Effect on the Neonatal Outcomes
The use of progestational agents in high-risk women has been recognized as an
appropriate method in preventing preterm birth as well as a method that has a positive
effect on neonatal outcomes. The use of progestational agents to prevent preterm birth
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was found to be statistically associated with decreased neonatal morbidity (Sotiriadis,
Papatheodorou & Markydimas, 2012; Fonesca et al., 2007; Rai et al. 2009), perinatal
death (Berghella et al., 2010; Rode et al., 2009), respiratory distress syndrome (Rode et
al., 2009; Hassan et al., 2011), necrotizing enterocolitis (Rode et al., 2009; Meis et al.,
2003), intraventricular hemorrhage (Dodd et al., 2005; Meis et al., 2003), need for
supplemental oxygen (Meis et al., 2003), neonatal intensive care unit (NICU) admissions
(Sotiriadis, Papatheodorou & Markydimas, 2012), NICU length of stay (Rai et al., 2009),
higher birth weights (Sanchez- Ramos, Kaunitz, & Delke, 2005; Tita & Rouse, 2009;
Dodd et al., 2005; Rai et al., 2009; Hassan et al., 2011), and higher APGAR scores (Rai
et al., 2009).
Some studies however did not have statistically significant results between the
progestational group and the placebo groups. However, these results generally did not
focus on neonatal outcomes but rather focused on preterm labor, hospital admissions,
antenatal corticosteroid therapy, and tocolytic therapy (Rode et al., 2009; SanchezRamos, Kaunitz, & Delke, 2005). Other studies showed that there was no difference
between the groups in infant morbidity or mortality rates or other maternal or neonatal
outcome measures meaning they were not better or worse (O’Brien et al., 2007;
Mackenzie et al., 2006; Cetingoz et al., 2011).
The evidence that was identified in regards to the use of progestational agents
having a positive effect on neonatal outcomes is overwhelming. The quality of evidence
was rated as high and good through the Johns Hopkins Research Evidence Appraisal
Tool and despite some studies identifying no significant effects on the outcome measures,
no studies identified that the use of progesterone caused harm on neonatal outcomes.
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Future Research
There is a need for further research focusing specifically on multiple gestation
pregnancies and pregnancies with known fetal anomalies and the use of progestational
agents. Significant research has focused on singleton gestation pregnancies and
pregnancies with known fetal anomalies excluded from these research studies.
Additionally, further research needs to be conducted in regards to optimal administration
route and timing of administration. The lack of studies investigating cost-effectiveness
and route of administration necessitates further studies.
Application and Integration of Theoretical Framework
Betty Neuman’s Systems Theory supports the nursing goal to keep the client well
and stable by integrating appropriate interventions (Reed, 1993). There are three levels of
prevention used to attain, maintain, and retain wellness - primary, secondary, and tertiary
(Reed, 1993). Primary prevention is aimed at decreasing risk factors and increasing the
FLD’s ability to withstand environmental stressors, secondary prevention comes into
effect when the NLD is disrupted and it is aimed at strengthening at protecting the basic
structure and strengthening the LR, and finally tertiary prevention focuses on helping
treating the client in order to promote a healthy return to a wellness state (Reed, 1993).
Until recently, preterm birth has largely focused on the tertiary level of prevention
to delay delivery in women presenting with acute preterm labor (Norwitz, 2015). The
rates of preterm labor, preterm birth, and complications in relation to these factors were
contributing to suffering and it is necessary to intervene sooner with primary or
secondary prevention strategies to improve these outcomes.
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Women may be at risk for preterm birth if they have a personal history of
previous spontaneous preterm birth or have a sonographically identified short cervix. By
identifying women at risk for preterm birth early in their pregnancies we will be utilizing
primary prevention and by determining and implementing the safest method of
progesterone supplementation in high-risk women in an effort to avoid preterm birth we
will be encompassing secondary prevention. By acting upon these assessments, the
provider will have a better chance of being successful in keeping the client and the fetus
in a state of wellness and health. Prevention as intervention is the basis of health
promotion and we need to to encompass primary, secondary, and tertiary prevention in
order to be successful.
Conclusion
The major findings of this critical review emphasize the benefits of the use of
progestational agents in reducing preterm birth and neonatal outcomes. The literature
supports the use of progestational agents in women at a high-risk for preterm labor or
preterm birth. By reducing the rate of preterm birth, there is potential to reduce many
other linked outcomes such as neonatal outcomes and costs related to premature delivery
complications. Nurse leaders have the ability and responsibility to discuss a woman’s risk
factors and obstetrical history at antenatal visits to determine their risk for preterm
delivery. By identifying those at risk early on, strategies such as prophylactic
progesterone administration may be implemented in those identified as appropriate
candidates. Betty Neuman’s Systems theory provides a theoretical framework to improve
nursing practice for those at risk for preterm birth by identifying the benefits of primary,
secondary, and tertiary interventions. The nursing body of knowledge can be
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strengthened through further research focused on route and timing of administration,
cost-effectiveness, and investigating the potential effects on multiple gestation
pregnancies and pregnancies with known fetal anomalies as these factors were not
addressed fully in this literature review.
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Critical Appraisal Matrix

Citation and
Level/Quality
Berghella, V., Figueroa,
D., Szychowski, J. M.,
Owen, J., Hankins, G.
D., Iams, J. D., & ...
Guzman, E. R. (2010).
17-alphahydroxyprogesterone
caproate for the
prevention of preterm
birth in women with
prior preterm birth and a
short cervical length.
American Journal of
Obstetrics &
Gynecology, 202(4),
351.e1-351.e6.
doi:10.1016/j.ajog.2010.
02.019
Level I/Good

Purpose

Sample

Design

Measurement

Results/Conclusion

Recommendations

To estimate
the effect of
17P for
prevention of
preterm birth
in women
with prior
spontaneous
preterm birth,
cervical length
<25 mm, with
and without
ultrasoundindicated
cerclage.

15 US clinical centers
from January 2003 to
November 2007.
Exclusion criteria was
fetal anomaly, planned
history-indicated
cerclage, and clinically
significant maternalfetal complications.
Inclusion criteria was
singleton gestations,
prior spontaneous
preterm birth (17-33+6
weeks), and short
cervical length < 25 mm
measured between 1622+6 weeks. 300
women were analyzed.
Of these 300 women,
148 were randomized to
cerclage and 152 were
randomized to no
cerclage.

The study
conducted
secondary
analysis of the
Eunice
Kennedy
Shriver
National
Institute of
Child Health
and Human
Development
was conducted
sponsored
randomized
trial evaluating
cerclage for
women with
singleton
gestations, prior
spontaneous
preterm birth
(17-33+6
weeks), and
short cervical
length < 25 mm
measured
between 1622+6 weeks.

The primary outcome of
this secondary analysis
was preterm birth < 35
weeks. Secondary
outcomes included birth <
7 days from
randomization; preterm
birth <24, <28, <32, and
<37 weeks; and perinatal
death. The primary
outcome and other
categorical variables were
compared with x2 tests and,
where appropriate, the
Fisher exact test.
Continuous variables were
analyzed using the t test
and Wilcoxon rank sum
test where appropriate.
Differences in time to birth
were assessed with
Kaplan-Meier curves and
the log rank test.
Multivariable logistic
regression and Cox
proportional hazard models
were considered possible
cofounders for outcomes of
preterm birth <35 weeks
and time of birth,
respectively. An alpha
level of <0.05 was used to
represent statistical
significance

In 300 women, 17P
had no effect on
preterm birth <35
weeks in either
cerclage or nocerclage groups.
Only preterm birth
<24 weeks and
perinatal death were
significantly lower
for those with 17P
in the no-cerclage
group.

17P had no additional benefit for
prevention of preterm birth in women
who had prior spontaneous preterm birth
and got ultrasound-indicated cerclage for
cervical length <25 mm. In women who
did not get cerclage, 17P reduced previable birth and perinatal mortality.
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Citation and
Level/Quality
Cahill, A. G.,
Odibo, A. O.,
Caughey, A.
B., Stamilio,
D. M.,
Hassan, S. S.,
Macones, G.
A., &
Romero, R.
(2010).
Universal
cervical length
screening and
treatment with
vaginal
progesterone
to prevent
preterm birth:
A decision
and economic
analysis.
American
Journal of
Obstetrics &
Gynecology,
202(6),
548.e1548.e8.
doi:10.1016/j.
ajog.2009.12.
005
Level III/High

Purpose

Sample

Design

Measurement

Results/Conclusion

Recommendations

To estimate
which
strategy is
most costeffective for
the
prevention of
preterm birth
and
associated
morbidity.

A MEDLINE and
PubMed literature
search was conducted
using the key words
‘preterm birth,
premature birth,
preterm labor, short
cervix, and
progesterone’ and
searched for pertinent
references in
identified
bibliographies. The
search was restricted
to human subject data
that was published in
the English language
in the last 14 years.
Exclusions were any
case reports or series,
meta-analyses, or
review articles.
Studies without
control groups were
included only for
prevalence estimates
of rare events.

A decision analytic model was
designed to compare 4
strategies: (1) the strategy of
universal screening of cervical
length with transvaginal
ultrasound at the time of
routine anatomic survey and
treatment with daily vaginal
progesterone for women with a
short cervix, (2) cervical length
screening for women at
increased risk for preterm birth
(i.e., previous spontaneous
preterm birth) and treatment
with vaginal progesterone for
women with a cervical length <
1 mm, (3) no cervical length
and treatment with 17- OHP- C
based on obstetric history, and
(4) no screening or treatment.
Decision analytic and costeffectiveness analyses to
estimate which of 4 strategies
was superior based on qualityadjusted life-years, cost in US
dollars, and number of preterm
births prevented.

Probability and utility point
estimates were calculated as
the sample size-weighted
means of estimates from the
included studies; their ranges
were defined by the extreme
low and high values reported
in the literature. For estimates
derived from a single source,
a range was defined by 95%
CI that was calculated from
binomial distribution. Cost
estimates were derived from
the literature and, when
unavailable, from local
sources based on Medicaid
reimbursement rates. When
local estimates were used,
charges were multiplied by a
cost-charge ratio of 0.6 as an
approximation to third-party
reimbursements. Base-case
cost effectiveness analysis
was performed that compared
strategies 1-3 with each other
and with strategy 4. A
threshold of $100,000 was
considered cost-effective.
Sensitivity analyses, threshold
analyses, and Monte Carlo
simulation were used.

Universal sonographic
screening for cervical length
and treatment with vaginal
progesterone was the most
cost-effective strategy and
was the dominant choice over
3 alternatives: cervical length
screening for women at
increased risk for preterm
birth and treatment with
vaginal progesterone; riskbased treatment with 17OHP-C without screening; no
screening or treatment.
Universal screening
represented savings of $1339
($8323 vs $9664), when
compared with treatment with
17-OHP-C, and led to a
reduction of 95,920 preterm
births annually in the United
States.

Universal sonographic
screening for short cervical
length and treatment with
vaginal progesterone
appears to be cost-effective
and yields the greatest
reduction in preterm birth at
<34 weeks’ gestation.
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Purpose
To evaluate
whether the
prophylactic
administration
of vaginal
progesterone
would reduce
the preterm
birth rate in
high-risk
population
including
singleton and
twin
pregnancies.

Sample

Design

Measurement

Results/Conclusion

This study
included a
sample of
women from
the Department
of Obstetrics
and
Gynecology
Clinic of
Zeynep Kamil
Women and
Children
Diseases
Education and
Research
Hospital in
Isstanbul from
December
2004 to
February 2007.
150 high-risk
pregnancies
were analyzed.
Risk groups
included prior
spontaneous
preterm birth,
twin
pregnancy, and
uterine
malformation.

Randomized,
double blind,
placebo
controlled
study.
Micronized
progesterone
or placebo
(100 mg) was
administered
daily by
vaginal
suppository
between 24
and 34 weeks
of gestation.

The primary
outcome measure
was the ratio of
preterm delivery
with both the
progesterone and
placebo groups. The
secondary outcome
measures included
the frequency of
delivery <34 weeks
and the frequency of
preterm labor and
neonatal outcomes.
Analysis was
performed according
to intention-to-treat
principle. The x2 test
or Fisher exact test
were used for
categoric variables.
The two-tailed
student t test was
used for continuous
variables. A p value
of 0.05 was
considered
significant.

There was a statistically
significant difference in the
rate of preterm labor between
placebo and progesterone
groups. More women
delivered before 37 weeks in
the placebo group than in the
progesterone group.
Administering progesterone
also reduced preterm birth
before 34 weeks of gestation.
There was no significant
difference in neonatal death
between placebo and
progesterone groups.

Recommendations
Prophylactic vaginal progesterone reduced the rate
of preterm labor and preterm delivery in high-risk
pregnancies. Additional studies will need to study
large population to confirm progesterone effects in
multiple pregnancies and pregnancies with uterine
malformation, and to evaluate neonatal effects of
progesterone therapy in high-risk pregnancies.
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Purpose

Sample

Design

Measurement

To compare
vaginal
progesterone
and cervical
cerclage
directly for the
prevention of
preterm birth
in women
with a
sonographic
short cervix
(<25 mm) in
the midtrimester,
singleton
gestation, and
a history of
previous
spontaneous
preterm birth.

MEDLINE, EMBASE, CINAHL, and LILACS
(all from inception to October 31, 2012), the
Cochrane Central Register of Controlled Trials &
ISI Web of Science (1960 to October 31, 2012),
research registers of ongoing trials, and Google
scholar were searched using a combination of
keywords and text words related to progesterone,
cervical cerclage, short cervix, and preterm birth.
Congress proceedings of international society
meetings of maternal-fetal reproductive medicine
and international meetings on preterm birth,
reference lists of identified studies, textbooks,
previously published systematic reviews, and
review articles were also searched. Experts in the
field were contacted to identify further studies.
Quasi-randomized studies were excluded.
Randomized controlled trials in which
asymptomatic women with a sonographic short
cervix (cervical length, <25 mm) in the midtrimester, singleton gestation, and previous
spontaneous preterm birth at <37 weeks of
gestation were allocated randomly to receive
vaginal progesterone vs placebo/no treatment or
cerclage vs no cerclage for prevention of preterm
birth were included. Trials were included if the
primary aim of the study was to (1) prevent
preterm birth in women with such characteristics;
or (2) prevent preterm birth in women with other
characteristics, but outcomes were available for
patients with a pre-randomization cervical length
<25 mm in the mid trimester, singleton gestation,
and previous preterm birth. All published studies
that were deemed suitable were retrieved and
reviewed independently by 2 authors to
determine inclusion. 9 randomized control trials
were included (662 women). Sample sizes ranged
from six to 301 women. Four studies were of
vaginal progesterone versus placebo (158
women) and 5 evaluated cerclage vs no cerclage
(504 women).

This study was a systematic
review with adjusted indirect
meta-analysis of randomized
controlled trials. It was
conducted based on a
prospectively prepared protocol
and is reported with the use of
the Preferred Reporting Items
for Systematic reviews and
Meta-analyses (PRISMA)
guidelines for meta-analyses of
randomized controlled trials and
suggested guidelines for IPD
and indirect meta-analyses. The
Cochrane risk of bias tool was
used to evaluate bias in the
following areas: random
sequence generation, allocation
concealment, blinding of
participants and personnel,
blinding of outcome assessment,
incomplete outcome data,
selective reporting and other
bias. Two reviewers
independently assessed risk of
bias. Intention-to-treat data from
two previous individual patient
data meta-analyses were
extracted in order to calculate
risk ratios. Both pair-wise direct
comparisons, and indirect
comparisons were performed.
For the direct comparisons, a
fixed-effect model was used if
there was no evidence of
substantial heterogeneity;
otherwise a random effects
model was used. The numberneeded-to-treat was also
calculated. Publication bias was
assessed using funnel plots and
the Egger test.

The primary outcome
measures were
preterm birth <32
weeks of gestation
and composite
perinatal morbidity
and mortality
(defined as the
occurrence of any of
the following events:
respiratory distress
syndrome, grade
III/IV intraventricular
hemorrhage,
necrotizing
enterocolitis,
neonatal sepsis,
bronchopulmonary
dysplasia, or
perinatal mortality).
Secondary outcome
measures included
preterm birth at <37,
<35, and <28 weeks
of gestation,
respiratory distress
syndrome, grade
III/IV intraventricular
hemorrhage,
necrotizing
enterocolitis,
neonatal sepsis,
bronchopulmonary
dysplasia, or
perinatal mortality, a
composite neonatal
morbidity outcome,
birthweight <1500 g
and <2500g, and
admission to the
NICU.

Results/
Conclusion
Direct
comparisons
results
displayed
that both
vaginal
progesterone
and cerclage
were
associated
with
significant
reductions in
the risk of
pre-term
birth at less
than 32
weeks of
gestation and
composite
perinatal
morbidity
and mortality
compared to
placebo/no
cerclage. On
the other
hand, the
indirect
comparisons
revealed that
there were
no
significant
differences
between
vaginal
progesterone
and cerclage
for any
outcome
measures.

Recommendations
Both vaginal
progesterone and
cerclage significantly
reduce the risk of
preterm birth in
women with a
sonographic short
cervix in the mid
trimester, singleton
gestation and
previous preterm
birth. Indirect
comparisons
indicated equal
efficacy. Selection of
the optimal treatment
needs to consider
adverse events, cost,
and patient/clinician
preferences. Medical
treatment with
vaginal progesterone
could decrease the
risks associated with
anesthesia and a
surgical procedure;
therefore, it is
important to disclose
the availability of a
non-surgical
therapeutic choice to
patients with a
history of preterm
birth and a short
cervix. The authors
estimated that any
future trial which
directly compared
progesterone with
cerclage would need
to recruit around 800
patients.
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Purpose

Sample

Design

Measurement

Results/Conclusion

Recommendations

To evaluate the
effect of
prophylactic
vaginal
progesterone in
decreasing
preterm birth rate
in a high-risk
population.

The study was performed
in the Obstetrics Clinic, at
Hospital das Clinicas,
University of Sao Paulo
Medical School, a tertiary
medical center, in Brazil.
Women at high risk for
preterm delivery were
considered to be those in
the presence of at least one
previous spontaneous
preterm birth, prophylactic
cervical cerclage, and
uterine malformation.
Multiple gestation and
fetal malformations were
excluded. Among the
women who sought highrisk prenatal care, 257
asymptomatic high-risk
singleton pregnant women
for preterm delivery were
followed from February 2,
1996 to March 30, 2001.
Fifteen patients were lost
to follow-up or withdrew
from the study. Therefore
the data analyses 142 highrisk singleton pregnancies.

This study was a
randomized, doubleblind, placebocontrolled trial in which
progesterone (100 mg)
or placebo was
administered daily by
vaginal suppository and
all patients underwent
uterine contraction
monitoring with an
external
tocodynamometer once
a week for 60 minutes,
between 24 and 34
weeks’ gestation. A
positive test was
considered when there
were four or more
contractions per hour
before the 30th week of
gestation and from 30
weeks onward, 6 or
more contractions per
hour. Preterm labor was
defined as two or more
regular uterine
contractions every 10
minutes, recorded by
external
tocodynamometer,
associated with cervical
changes, represented by
a dilation of more than 2
cm, or the presence of
progressive dilation or
effacement of the
cervix. A preterm
delivery was defined as
birth before 37 weeks of
pregnancy.

Progesterone (n = 72) and
placebo (n = 70) groups
were compared for
epidemiologic
characteristics, uterine
contraction frequency, and
incidence of preterm birth.
Data were compared by x2
analysis and Fisher exact
test. The two-tailed
Student t test was used for
continuous variables and
the Wilcoxon rank sum test
was used for interval
variables. Kaplan-Meier
survival analysis was used
to determine the
relationship between the
administration of
prophylactic vaginal
progesterone and preterm
birth. The long-rank x2 test
was used to compare the
differences in the
generated survival curves.
A P value of .05 was
considered significant.

Of 142 cases, there
were 30 preterm
births (preterm birth
rate of 21.1%).
Differences in uterine
activity were found
between the
progesterone and
placebo groups and
in preterm birth
between progesterone
and placebo. More
women were
delivered before 34
weeks in the placebo
group than in the
progesterone group.

This study indicates that the
prophylactic use of natural
progesterone may be
associated with the decrease
of uterine contractions.
However, the lower incidence
of preterm delivery in the
progesterone group cannot be
explained by these findings
because uterine activity was
only assessed weekly for just
one hour. This study strongly
suggests that, by
administering vagina natural
progesterone in pregnant
women with high risk for
preterm delivery, it is possible
to decrease the frequency of
preterm birth. However,
multi-center randomized
clinical trials with other risk
factors are required to
confirm these results.
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Purpose

Sample

Design

Measurement

Results/Conclusion

Recommendations

To assess the role
of progesterone in
preterm birth
prevention by
using the best
available evidence
form the current,
randomized,
controlled trial
literature.

Types of studies
included were
published
randomized,
controlled trials in
which progesterone
(either
intramuscular or
vaginal
administration) was
compared with
placebo or no
treatment. Quasirandomized studies
were included. The
types of
participants in these
studies were
women with a
singleton pregnancy
in which
progesterone was
administered for the
prevention of
preterm birth. The
types of outcomes
measured were
adverse outcomes
for the infant/child
and the woman as
well as the costs of
health care. Seven
randomized
controlled trials
were identified that
met this criteria.

A MEDLINE
search (from
1966 to the
present; date of
last search
January 2005)
were performedusing the key
words
progesterone,
pregnancy,
preterm birth,
preterm labor,
and randomized
controlled tria0
in order to
identify
randomized,
controlled trials
in which
progesterone
(either
intramuscular or
vaginal
administration)
was compared
with placebo or
no treatment.
Data was
extracted and
meta-analyses
were performed.

Meta-analyses were
performed by using
relative risks (RR) and
95% confidence
intervals for binary
outcomes, and
weighted mean
differences for
continuous outcomes.
Planned subgroup
analyses were by
means of dose and
frequency of
progesterone
administration and
mode of administration
(intramuscular versus
vaginal). Sensitivity
analyses were
performed in order to
take account of any
differences in use, only
in women considered
to be at ‘high’ risk for
preterm birth, and
study quality. The
outcomes measured
were preterm birth
(<37 weeks),
birthweight <2.5kg,
perinatal death,
stillbirth, neonatal
death, respiratory
distress syndrome,
ventilatory support,
intraventricular
hemorrhage,
necrotizing
enterocolitis, patent
ductus arteriosus,
sepsis, and retinopathy
of prematurity.

Women who
received
progesterone were
statistically
significantly less
likely to give birth
before 37 weeks, to
have an infant with
birth weight of <2.5
kg, or to have an
infant diagnosed
with intraventricular
hemorrhage.

For progesterone supplementation to be
advocated for women at the risk of preterm
birth, the prolongation of gestation
demonstrated in this meta-analysis must
translate into improved infant outcomes,
including a reduction in mortality. There is
currently insufficient information to allow
recommendations regarding the optimal dose,
route, and timing of administration of
progesterone supplementation. Further large
trials are required in order to provide reliable
information on the maternal outcomes including
side-effects associated with treatment, maternal
views, preferences for care, and satisfaction
with care.
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Purpose

Sample

Design

Measurement

Results/Conclusion

Recommendations

To evaluate
the effect of
vaginal
progesterone
on the
incidence of
spontaneous
early preterm
delivery in
asymptomatic
women found
at routine midtrimester
screening to
have a short
cervix.

The study was
conducted from
September 2003 to
May 2006 in five
maternity hospitals
around London. All
women with
singleton or twin
pregnancies who
were undergoing
routine
ultrasonography at
20 to 25 weeks of
gestation for
examination of fetal
anatomy or growth
were given the
option of
transvaginal
ultrasonographic
measurement of
cervical length as a
predictor of
spontaneous early
preterm delivery.
The exclusion
criteria were major
fetal abnormalities,
painful regular
uterine contractions,
a history of ruptured
membranes, or a
cervical cerclage.
Women with a
cervical length of
15 mm or less were
invited to take part
in this study. 413
women qualified for
this study but 250
women agreed to
participate.

The study was
a multi-center,
randomized,
double-blind,
placebocontrolled
trial. The 250
women who
agreed to
participate in
the trial were
randomly
assigned to
receive
vaginal
progesterone
(200 mg each
night) or
placebo from
24 to 33+6
weeks of
gestation.

The primary outcome was
spontaneous delivery before 34
weeks. The secondary outcome
measures were birth weight, fetal or
neonatal death, major adverse
outcomes before discharge form the
hospital (intraventricular
hemorrhage, respiratory distress
syndrome, retinopathy of
prematurity, or necrotizing
enterocolitis), and need for neonatal
special care (admission to the NICU,
ventilation, phototherapy, treatment
for proven or suspected sepsis, or
blood transfusion). The analysis was
performed according to the
intention-to-treat principle. Baseline
data for the progesterone and
placebo groups were summarized by
the median and interquartile range.
Comparisons between groups were
performed with the use of the MannWhitney U test. Univariate
comparisons of dichotomous data
were performed with the use of
Fisher’s exact test. Effect
modification was assessed with the
use of the Mantel-Haenszel test for
homogeneity. Multivariable analysis
was performed by logistic
regression. The risk of spontaneous
preterm birth from randomization
until 34 weeks was assessed using
Kaplan-Meier analysis. Hazard ratios
were estimated with the use of the
Cox proportional-hazards model,
with a formal test of the
proportional-hazards assumption.
Logistic regression was used to
assess the risk of adverse events in
the offspring.

Spontaneous delivery
before 34 weeks of
gestation was less frequent
in the progesterone group
than in the placebo group.
Progesterone was
associated with a
nonsignificant reduction in
neonatal morbidity. There
were no serious adverse
events associated with the
use of progesterone. In
conclusion, in women with
a short cervix, treatment
with progesterone is a
method to reduce the rate
of spontaneous early
preterm delivery.

The article states that the American
College of Obstetrics and Gynecologists
Committee on Obstetric Practice
recommends that women who have had a
previous preterm delivery should be
considered for treatment with
progesterone in a subsequent pregnancy
but notes that the ideal formulation,
optimal route of delivery, and long-term
safety of progesterone remain unknown.
Although in this trial progesterone
proved effective in reducing spontaneous
preterm birth in women with cervical
lengths less than 15 mm, it should be
noted that less than one third of the
women who had spontaneous preterm
delivery met this criterion. Future
randomized trials should investigate the
effectiveness of progesterone in other
high-risk populations. The findings of
this study provide support for a strategy
of routine screening of pregnant women
by ultrasonographic measurement of
cervical length and the prophylactic
administration of progesterone to those
with a short cervix.
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Purpose

Sample

Design

Measurement

Results/Conclusion

Recommendations

To
determine
the efficacy
and safety
of using
micronized
vaginal
progesteron
e gel to
reduce the
risk of
preterm
birth
(before 33
weeks) and
associated
neonatal
complicatio
ns in
asymptoma
tic women
with a midtrimester
sonographi
c short
cervix.

44 centers in 10
countries.
Included 465
women with
singleton
pregnancies
between 19+0
to 23+6 weeks
of gestation that
had
transvaginal
sonographic
short cervical
lengths (1020mm) but
were
asymptomatic
(no signs or
symptoms of
preterm labor).
Of these 458
women, 16%
had a history of
a previous
preterm birth
between 20 and
35 weeks of
gestation.

Multi-center,
randomized, doubleblind, placebo-controlled
trial. Subjects were
allocated randomly to
receive vaginal
progesterone gel or
placebo beginning at 20
to 23+6 weeks.
Randomization sequence
was stratified by center
and history of a previous
preterm birth. Women
self administered the drug
once daily in the
morning. The women
were instructed to return
to study center every 2
weeks. The study drug
was continued until 36+6
weeks’ gestational age,
rupture of membranes or
delivery, whichever
occurred first.

The primary outcome of this study was
preterm birth before 33 weeks of
gestation. The key secondary outcomes
were neonatal morbidity, including
respiratory distress syndrome,
bronchopulmonary dysplasia, Grade III or
IV intraventricular hemorrhage,
periventricular leukomalacia, proven
sepsis, necrotizing enterocolitis, and
perinatal mortality (fetal death or neonatal
death). Other pre-specified secondary
outcomes included preterm birth before
28, 35, and 37 weeks of gestation,
neonatal length, weight and head
circumference at birth and incidence of
congenital abnormalities. And finally, the
frequency of adverse events related to
treatment was also assessed. The primary
endpoint of the study, preterm birth before
33 weeks, was analyzed using the
Cochran-Mantel-Haenszel (CMH) test.
Analysis of the primary efficacy endpoint
was also performed using multivariable
logistic regression, in which the following
variables were included: treatment group,
poled study site, risk strata, gestational age
at first dose, maternal age, cervical length,
body mass index, and race. RR with 95%
CI was used as the measure of effect. The
CMH test was also used for the analysis of
the ordinal composite scores in which a
modified ranking procedure (modified
ridits) was used to calculate the sum of the
expected values for each of the ordinal
categories for each of the treatment
groups. The ranking procedure is
equivalent to non-parametric van Elteren
scores. The RR for the primary endpoint
was calculated unadjusted, partially
adjusted (for pooled study and risk strata),
as well as fully adjusted using
multivariable logistic regression.

Of 465 women randomized,
seven were lost to followup, & 458 (vaginal
progesterone gel, n = 235;
placebo, n = 223) were
included in the analysis. The
results revealed that women
allocated to receive vaginal
gel progesterone without a
history of preterm birth had
a lower rate of preterm birth
before 33 weeks than did
those allocated to placebo.
However, the reduction in
the rate of preterm birth in
women with a prior history
of preterm birth between 20
and 35 weeks of gestation
did not reach statistical
significance. Vaginal
progesterone was also
associated with a significant
reduction in the rate of
preterm birth before 28
weeks & 35 weeks,
respiratory distress
syndrome, any neonatal
morbidity or mortality
event, & birth weight <
1500 g. There were no
differences in the incidence
of treatment-related adverse
events between the two
groups. The administration
of vaginal progesterone gel
to women with a
sonographic short cervix in
the mid-trimester is
associated with a 45%
reduction in the rate of
preterm birth before 33
weeks of gestation with
improved neonatal outcome.

To date, no intervention in an
asymptomatic patient with a
risk factor has demonstrated
both a reduction in preterm
birth and an improvement in
infant outcome, without a
safety signal. The results of
this trial indicate that a
combined approach, in which
transvaginal sonographic
cervical length is used to
identify patients at risk for
preterm delivery, followed by
the administration of vaginal
progesterone gel from the
mid-trimester of pregnancy
until term, reduces the rate of
both preterm birth before 33
weeks of gestation and
respiratory distress syndrome,
the most common
complication of preterm
neonates. The main
implication of this study for
clinical practice is that
universal screening of women
with transvaginal sonography
to measure cervical length in
the mid-trimester to identify
patients at risk can now be
coupled with the use of
vaginal progesterone gel to
reduce the frequency of
preterm birth and improve
neonatal outcomes.
Additional studies are
necessary to determine if
treatment of women with a
short cervix in the early
second trimester may further
reduce the rate of preterm
delivery.
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Purpose
To determine
whether
progestational
agents, initiated in
the second
trimester or
pregnancy, reduce
the risk of delivery
less than 37 weeks,
among women at
increased risk of
spontaneous
preterm birth.

Sample
Three trials were
eligible for
inclusion.

Design
A systemic
review and metaanalysis was
done. Medline,
pre-Medline,
EMBASE, and
Cochrane Central
Register of
Controlled Trials
were searched.
RCTs with less
than 20% lost
follow-up were
included.

Measurement
The primary
outcome was
delivery less than
37 weeks’
gestation.
Secondary
outcomes included
delivery before 35,
34, and 32 weeks’
gestation, birth
weight less than
2500 g, birth
weight less than
1500 g,
spontaneous
abortion or
perinatal death,
measures of
serious neonatal
morbidity, and
congenital
abnormalities. The
relative risk and
95% CI for
dichotomous
variables and
weighted mean
difference and
95% CI for
continuous
variables, with the
use of the
DerSimonian and
Laird randomeffects model was
done.

Results/Conclusion
There was a
significant reduction
in risk delivery less
than 37 weeks with
progestational
agents. There was no
significant effect on
perinatal mortality
or serious neonatal
morbidity.

Recommendations
Progestational agents, initiated in the
second trimester of pregnancy, may reduce
the risk of delivery less than 37 weeks’
gestation, among women at increased risk
of spontaneous preterm birth, but the effect
on neonatal outcome is uncertain. Larger
randomized controlled trials are required to
determine whether this treatment reduces
perinatal mortality or serious neonatal
morbidity.
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Purpose

Sample

Design

Measurement

Results/Conclusion

Recommendations

To aim of this
study was to
assess the
efficacy and
tolerability of
vaginal
compared
with
intramuscular
progesterone
in reducing
the rate of
recurrent
preterm birth
before 34
weeks
gestation.

The study was conducted at Armed
Forces Hospital Southern Region,
Khamis Mushyat, Kingdom of
Saudi Arabia. Eligibility criteria for
this study included women of any
age, any parity, with singleton
pregnancies, a gestation between
14 and 18 weeks, and a previous
history of one or more midtrimester preterm births, or cerclage
suture inserted in a previous
pregnancy but not in the current
pregnancy. Exclusion criteria
included fetal anomaly or loss,
advanced cervical dilation,
membranes bulging into the vagina
in asymptomatic women, history of
ruptured membranes, short cervix
(<25 mm measured between 14 and
18 weeks gestation), or significant
funneling(>25%), women who
planned to undergo cervical
cerclage or who already had
cerclage inserted at another
hospital, major chronic medical
disorder (such as chronic
hypertension, chronic renal disease,
or progestational diabetes mellitus,
because these conditions would
increase the risk of preterm birth
and potentially confound the
primary study outcome), multiple
gestational pregnancies, and any
contraindication for progesterone
therapy (known active liver disease
or active thromboembolism). Of
the 547 women eligible for the
study, 518 women consented to
participate.

The study was
conducted as a
prospective,
randomized, nonblinded and nonplacebo controlled
trial. The
participants
underwent simple
randomization using
a computergenerated random
list. The women
were randomized to
receive either 90 mg
of vaginal
progesterone gel
once daily (n= 262)
or 250 mg of
intramuscular
progesterone
weekly (n= 265).
Treatment began
between 14 and 18
weeks gestation and
continued until 36
complete weeks of
gestation, delivery,
or the occurrence of
premature rupture
of membranes or
preterm birth.

The primary outcome
measure was delivery
before 34 weeks of
gestation. The secondary
outcome measures were
preterm birth between 34
to 37 weeks of gestation
and neonatal outcomes
including birthweight,
neonatal death, and the
need for admission to the
NICU. Student’s t-test
was used for quantitative
data.

When all deliveries
before 34 weeks of
gestation were compared
between the groups,
vaginal progesterone was
associated with a lower
percentage of deliveries
than the intramuscular
preparation. This
association was also
observed between 28 and
32 weeks of gestation. No
statistically significant
difference was observed
between the groups
regarding delivers at
other weeks of gestation.
Adverse effects were
reported in 14.1% of
patients in the
intramuscular group and
in 7.5% of patients in the
vaginal group. The
intramuscular group
showed a significantly
higher rate of neonatal
intensive care unit
admission than the
vaginal progesterone
group. More data from
different populations are
needed to support the
results.

The use of vaginal progesterone
over intramuscular progesterone
administration shows a reduction
in recurrent preterm births and
fewer adverse effects. Given that
prophylactic intervention to
prevent preterm birth entails a
long duration of progesterone
administration, less invasive
forms of administration are
preferred. Further data regarding
the optimal route, dose, or
duration of progesterone is still
lacking, and it remains unknown
whether there is a dose-response
relation between progesterone
and its action to reduce preterm
birth. More research regarding
the mechanisms of progesterone
and cerclage in preterm birth
may help clinicians to
understand how these two
interventions can be used
together.
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Purpose
To test the
effectiveness of
17P as compared
with placebo in
the prevention of
recurrent preterm
delivery.

Sample
The sample for this
study was collected
throughout 19
clinical centers.
Women presenting
to these centers for
prenatal care were
screened for
eligibility to
participate in the
trial; criteria for
eligibility included a
history of
spontaneous preterm
delivery in a
previous pregnancy
and a current
pregnancy between
15 weeks and 20+3
gestation. Exclusion
criteria included
multifetal gestation,
known fetal
anomaly
progesterone or
heparin treatment
during the current
pregnancy, current
or planned cervical
cerclage,
hypertension
requiring
medication, a
seizure disorder, or
a plan to deliver
elsewhere. 463
women consented to
participate in the
study. There were
310 women in the
progesterone group
and 153 women in
the placebo group.

Design
This was a
double-blind,
placebocontrolled trial.
The women
were randomly
assigned by a
central data
center in a 2:1
ratio, to receive
either weekly
injections of
250 mg of 17P
or weekly
injections of an
inert oil
placebo;
injections were
continued until
delivery or to
36 weeks
gestation.

Measurement
The primary outcome was
preterm delivery before 37
weeks of gestation. Analysis
was performed according to
the intention-to-treat
principle. Continuous
variables were compared with
the use of the Wilcoxon ranksum test, and categorical
variables were compared with
the use of the chi-square or
Fisher’s exact test.
Prolongation of pregnancy
was assessed by life-table
methods, with the duration
considered being that between
the time of randomization and
the time a woman gave birth,
was lost to follow-up, or
reached 40 weeks of
gestation, which ever came
first. Curves for event free
survival were estimated to
account for differing
durations of gestation at
entry, and were tested with
the log-rank test.

Results/Conclusion
Treatment with 17P
significantly reduced the
risk of delivery at less
than 37 weeks of
gestation, delivery at
less than 35 weeks
gestation, and delivery
at less than 32 weeks
gestation. Infants of
women treated with 17P
had significantly lower
rates of necrotizing
enterocolitis,
intraventricular
hemorrhage and need
for supplemental
oxygen.

Recommendations
Weekly injections of 17P
resulted in a substantial
reduction in the rate of recurrent
preterm delivery among women
who were at particularly high
risk for preterm delivery and
reduced the likelihood of several
complications in their infants.

56

Citation and
Level/Quality
O'Brien, J. M., Adair,
C. D., Lewis, D. F.,
Hall, D. R., Defranco,
E. A., Fusey, S., & ...
Newton, E. (2007).
Progesterone vaginal
gel for the reduction
of recurrent preterm
birth: primary results
from a randomized,
double-blind,
placebo-controlled
trial. Ultrasound In
Obstetrics &
Gynecology, 30(5),
687-696.
doi:10.1002/uog.5158
Level I/Good

Purpose

Sample

Design

Measurement

Results/Conclusion

Recommendations

To determine
whether
prophylactic
administration of
vaginal
progesterone
reduces the risk of
preterm birth in
women with a
history of
spontaneous preterm
birth.

The study included
659 pregnant
women with a
history of
spontaneous
preterm birth
between 18+0 and
22+6 weeks of
gestation. The
women were
eligible for the trial
if they were
between 18 and 45
years of age with a
n estimated
gestational age
between 16+0 and
22+6 weeks, and
had a history of
spontaneous
singleton preterm
birth between 20+0
and 35+0 weeks of
gestation in the
immediately
preceding
pregnancy,
confirmed by
review of medical
records.

This study was a
randomized,
double-blind,
placebo-controlled,
multinational trial.
The patients were
assigned randomly
to once-daily
treatment with
either progesterone
vaginal gel or
placebo until either
delivery, 37 weeks’
gestation or
development of
preterm rupture of
membranes.

The primary
outcome was
preterm birth at <32
weeks of gestation
and to assess the
efficacy and safety
of progesterone
vaginal gel
compared with
placebo. The trial
was analyzed using
an intent-to-treat
strategy. Baseline
characteristics and
outcome data were
compared between
treatment groups
using chi-square or
Fisher’s exact test
for categorical
variables and using
ANOVA for
continuous
variables. The
duration of
pregnancy in the
placebo and
intervention groups
was evaluated using
survival analysis
(life-table analysis
and the KaplanMeier method). A
P-value of <0.05
was considered
statistically
significant.

Progesterone did not
decrease the
frequency of preterm
birth at <32 weeks.
There was no
difference between
the groups with
respect to the mean
gestational age at
delivery, infant
morbidity or
mortality or other
maternal or neonatal
outcome measures.

Prophylactic treatment with vaginal
progesterone did not reduce the frequency of
recurrent preterm birth (<32 weeks) in
women with a history of spontaneous
preterm birth. The effect of progesterone
administration in patients at high risk for
preterm delivery as determined by methods
other than history alone (e.g. sonographic
cervical length) requires further
investigation.
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Results/Conclusion

Recommendations

To
understand
the
potential
national
effect of
17P
preventive
therapy on
preterm
birth rates

The study defines “17P eligible” as singleton
births to multiparous women with onset of
prenatal care within the first 4 months of
pregnancy with a history of spontaneous birth.
Preterm birth is defined as less than 37
completed weeks of gestation and very preterm
as less than 32 completed weeks. Spontaneous
birth is defined as a non-induced vaginal
delivery. To estimate the number of pregnant
women in the United States who would be
eligible for 17P preventive therapy, the 2002
United States natality (birth certificate) file from
the National Center of Health Statistics, Centers
for Disease and Prevention. This database
includes information on all live births in the
nation. Studies have indicated, however, that
reporting of a woman’s history of a prior preterm
birth on the birth certificate may not be complete
and may underestimate the true occurrence of
this event. To address this potential limitation,
the data from longitudinal birth certificate files
from New Jersey and Missouri were also
analyzed for the rates of prior preterm birth and
recurrence of spontaneous preterm birth. Based
on the 2002 United States natality data, the
number of births to multiparous women with
single gestation was 2,313,718. From this
number, the estimated number of women who
did not meet the 16-20 weeks' prenatal care
entry period was subtracted. The resultant
2,037,292 births represent those women who
initiated care early enough to have been
candidates for 17P therapy. The New Jersey and
Missouri databases identified women who met
the inclusion criteria in the same fashion. The
averaged rates from the 2 states were 8.7% for
prior preterm birth and 1.3% for prior very
preterm birth.

Estimated
the number
of singleton
preterm
births
delivered to
women with
a history of
prior
spontaneous
preterm
birth who
accessed
prenatal
care within
the first 4
months
gestation by
analyzing
the sample.

Using 2002
national birth
certificate
data,
augmented by
vital statistics
from 2 states,
the estimated
number of
singleton
births
delivered to
women
eligible for
17P through
both a history
of
spontaneous
preterm birth
and prenatal
care onset
within the first
4 months of
pregnancy.

According to this
study’s calculations,
if 17P 9,870
preterm births,
might have been
prevented if eligible
women received
17P preventive
therapy. If 17P use
were restricted to
women with a
history of a
previous
spontaneous very
preterm birth, 2,163
preterm births
might have been
prevented. Among
the smaller cohort
of 2,037,292
spontaneous
singleton births to
multiparous women
with onset of
prenatal care during
the first 4 months of
pregnancy,
regardless of history
of preterm birth,
universal use of 17P
would have reduced
the preterm birth
rate in this cohort
from 9.4% to 8.5%,
reflecting an
estimated 11%
reduction, or an
absolute difference
of 0.9%, P < .001.

The use of 17P could reduce preterm birth
among eligible women, but would likely have
a modest effect on the national preterm birth
rate. Additional research is urgently needed to
identify other populations who might benefit
from 17P evaluate new methods for early
detection of women at risk, and develop
additional prevention strategies.
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Sample

Design

Measurement

Results/Conclusion

Recommendations

To calculate the
costs and cost
effectiveness of VP
gel versus placebo
using decision
analytic models
informed by
PREGNANT
patient-level data.

The PREGNANT
trial enrolled 459
pregnant women
with a cervical
length of 10-22 mm
and randomized
them to either VP
8% gel or placebo.

An economic
analysis of the
PREGNANT study
was done. The
PREGNANT study
was a randomized,
multi-center, clinical
trial that investigated
the safety and
effectiveness of VP
gel to decrease the
incidence of PTB
among women with
a short cervix, with
or without a history
of preterm birth.
Used a cost model to
estimate the total
cost of treatment per
mother and a costeffectiveness model
to estimate the cost
per PTB averted
with VP gel versus
placebo. Cost
consumptions were
based on 2010 US
healthcare services
reimbursements. The
cost model was
validated against
patient-level data.
Sensitivity analyses
were used to test the
robustness of the
cost-effectiveness
model.

The primary
measure was
determining the
total cost per mother
treated with VP gel
in PREGNANT.
Secondary measures
were cost
effectiveness of VP
gel in terms of cost
per preterm birth
averted.

The estimated cost
per mother was
$US23,079 for VP
gel and $US36,436
for placebo. The
cost-effectiveness
model showed a
savings of
$US24,071 per
preterm birth averted
with VP gel. VP gel
realized cost savings
and cost
effectiveness in 79%
of simulations.

Based on the findings from PREGNANT,
VP gel was associated with cost savings and
cost effectiveness compared with placebo.
Future trials designed to include cost metrics
are needed to better understand the value of
VP.
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Purpose
To evaluate
oral
micronized
progesterone
(OMP) to
prevent
preterm birth
(PTB).

Sample
The sample of women
was collected in the
Department of
Obstetrics and
Gynecology at the
University College of
Medical Science and
Guru Teg Bahadur
Hospital, Delhi,
between January 2005
and December 2006.
Inclusion criteria for
the study were
asymptomatic women
aged between 18 and
35 years who were
between 18 and 24
weeks of pregnancy,
with a history of at
least 1 spontaneous
preterm delivery
(between 20 weeks
and 36+6 weeks of
gestation) with a
singleton live
pregnancy. Women
with first trimester
bleeding, premature
rupture of
membranes, multiple
pregnancy, fetal
anomalies, or active
liver disease were
excluded from the
trial. A total of 150
women with at least
one PTB met the
inclusion criteria.

Design
A randomized,
double-blind,
placebo-controlled
trial in which the
study participants
received 100 mg
of OMP or
placebo twice a
day from
recruitment (18-24
weeks) until 36
weeks or delivery.

Measurement
Statistical analysis
was done using the
x2 test for
quantitative
variables Fisher
exact test for
quantitative
variables (small
sample size),
independent
sample t test to
compare
qualitative with
quantitative
variables, and
Mann-Whitney
test to compare
qualitative with
quantitative
variables (for nonnormalized data).

Results/Conclusion
PTB occurred in 29
women in the OMP
group compared
with 44 in the
control group. Mean
gestational age at
delivery was higher
in the OMP group.
Fewer PTB occurred
between 28 and
31+6 weeks of
gestation in the
OMP group.
Neonatal age at
delivery, birth
weight, NICU stay,
and Apgar scores
were more favorable
in the OMP group,
and fewer neonatal
deaths occurred.

Recommendations
OMP reduced the risk of PTB between 28
and 31+6 weeks of gestation, NICU
admissions, and neonatal morbidity and
mortality in high risk patients. Although
there were favorable results in the OMP
group, the study was limited to a single
hospital which is a huge limitation.
Extended follow-up is needed to determine
whether the drug exerts any long-term
adverse effects. A large multi-center study
with a higher number of patients and a
longer follow-up is needed to confirm its
efficacy and safety.
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Purpose
To provide an
update on the
preventive effect
of progesterone
on preterm birth
in singleton
pregnancies.

Sample
A search in the
PubMed, Embase,
and Cochrane
database was
performed using
the keywords:
pregnancy,
progesterone,
preterm
birth/preterm
delivery, preterm
labor, controlled
trial, and
randomized
controlled trial.
Inclusion criteria
was intramuscular,
vaginal, or oral
progesterone
starting treatment
during the second
trimester of
pregnancy in
singleton
pregnancies. Two
new randomized
controlled trials of
women with
previous preterm
birth were added
to the four
analyzed in the
2006 Cochrane
review, and the
meta-analysis was
done on all six
studies.

Design
A meta-analysis
was performed
on randomized
trials including
singleton
pregnancies with
previous preterm
birth.

Measurement
The trials were
compared and
results were
reported as RRs
with the
corresponding
95% CI using the
fixed effect
model. Risk
differences were
reported as the
risk in the placebo
groups minus the
risk in the
progesterone
groups.

Results/Conclusion
In women with a
singleton pregnancy
and previous
preterm delivery,
progesterone
reduces the rates of
preterm delivery
before 32 weeks,
perinatal death, as
well as respiratory
distress syndrome,
and necrotizing
enterocolitis in the
newborn. The risk
of admission for
preterm labor,
antenatal
corticosteroid
therapy, and
tocolytic therapy is
not decreased in
women who are
treated
prophylactically
with progesterone.
Women with a short
cervix or preterm
labor may also
benefit from
progesterone, but
further evidence is
needed to support
such
recommendations.

Recommendations
Based on previously published metaanalyses of data on women with a
singleton pregnancy and a history of
preterm birth, progesterone seems to have
a beneficial effect on pregnancy length
and some secondary neonatal outcomes.
Inclusion of the most recent studies in a
meta-analysis even shows that infant
survival is significantly increased in the
progesterone group compared to the
placebo group. The strengthening of
evidence should be considered in obstetric
practice. Follow up studies should focus
on possible metabolic complications in
the mother or the offspring as an
observational study has shown that there
is an association between progesterone
treatment and the risk of developing
gestational diabetes.
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Purpose

Sample

To perform
an updated
systematic
review with
metaanalysis to
further
elucidate the
efficacy of
progestationa
l agents for
the
prevention of
preterm
births in
patients at
elevated risk.

Computerized databased,
references in published
studies, and textbook
chapters in all languages
were used to identify RCTs
evaluating the use of
progestational agents for
the prevention of preterm
births in women at
elevated risk. RCT’s that
compared progestational
agents with placebo for
patients at risk for preterm
birth and evaluated at least
one of the following:
delivery before 37 weeks
of gestation, birth weight
less than 2,500 g,
threatened preterm labor,
RDS, and perinatal
mortality. Ten studies met
inclusion criteria for this
review. A total of 1,339
subjects were enrolled in
these ten trials.

Design
Meta-analysis of
RCTs.

Measurement

Results/Conclusion

Recommendations

The primary outcomes
assessed were preterm
delivery and perinatal
mortality. For each study
with binary outcomes,
and odds ratio with 95%
CI was calculated for
selected outcomes.
Homogeneity was tested
across the studies.
Estimates of odds ratios
for dichotomous
outcomes were calculated
using fixed effects
(Mantel Haenszel) and
random effects
(DerSimonian and Laird)
models. Number needed
to treat was calculated for
outcomes showing
significant benefit from
the use of progestational
agents. To determine the
combinability of
individual studies, a
formal test of
heterogeneity by using
the Mantel-Haenszel
method was done.

Compared with women
allocated to receive placebo,
those who received
progestational agents had lower
rates of preterm delivery.
Similar results were noted
when comparing patients who
were specifically treated with
17P. Additionally, subjects
allocated to receive 17P had
lower rates of birth weights less
than 2,500 g. No differences in
rates of hospital admissions for
threatened preterm labor or
perinatal mortality were noted
for subjects receiving
progestational agents in general
or for those receiving only 17P
specifically.

The use of progestational agents and
17P reduced the incidence of preterm
birth and low birth weight outcomes.
Substantially less data supports the
efficacy of progestational agents in
the prevention of preterm births
among patients with multiple
gestations compared with singletons.
More research is needed in the area.
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Sample

Design

Measurement

Results/Conclusion

Recommendations

To quantify
the effect on
perinatal
outcome in
women
treated with
progesterone
for the
prevention
of preterm
birth

A search was done for literature
(last update December 2011) for
clinical trials in which
progesterone was given for
prevention of preterm birth in
pregnant women at risk compared
to placebo. MEDLINE and
SCOPUS searches used
combinations of the terms
‘progesterone’ and ‘preterm’.

This study was
a meta-analysis
of RCT’s. Data
extraction and
study quality
assessment
were
independently
performed by
two authors in
case of
disagreement a
consensus was
reached after
discussion
between the
two authors or
after evaluation
by a third
author. The
CONSORT
statement was
used for
addressing the
reporting
quality of the
RCTs included
in the metaanalysis. The
risk of bias in
the randomized
trials was
assessed with
the ‘Risk-ofbias’ tool from
the Cochrane
Collaboration.

The primary outcome
was the rate of neonatal
mortality, meaning the
number of deaths from
birth to under the age of
28 days, and perinatal
mortality. Secondary
outcomes were rates of
perinatal complications
(respiratory distress
syndrome, grade III/IV
intraventricular
hemorrhage,
necrotizing
enterocolitis, sepsis,
and retinopathy),
admission to the NICU,
and composite adverse
outcomes (the presence
of any perinatal
morbidity or mortality).
Comparisons were
made using the risk
ratio and the number
needed to treat was
calculated. The random
effects models
(DerSimonian and
Laird) were used for
data synthesis.

For singleton
pregnancies,
progesterone
reduced the rates
of neonatal death,
NICU admission,
and composite
adverse outcome.
No favorable effect
was observed in
multiple gestation
pregnancies.

The next step after testing the effects of
progesterone treatment on the rates of
preterm birth and immediate perinatal
complications is to examine its impact
on the longer-term neurodevelopment of
treated children.

Inclusion criteria: RCT’s;
progesterone vs placebo for the
prevention of preterm birth in
women at risk; women with
singleton pregnancy at risk for
preterm birth owing to previous
history or short cervix during the
second trimester or multiple
pregnancies.
Studies were excluded if there
was no adequate randomization
or no placebo group, the
administration of progesterone
was done in women with
symptoms of preterm labor,
bleeding, or rupture of
membranes, or if they did not
provide data on neonatal
outcomes.
Sixteen studies were included in
the meta-analysis.
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Purpose
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Design

Measurement

Results/Conclusion

Recommendations

To present a concise
review of more
recent data (since
2000) on
progesterone use
specifically for
preterm birth
prevention focusing
on pharmacologic
options, specific
clinical indication,
and expected
benefits.

Of a total of 17
reports identified,
there were 8 clinical
trials, 6 metaanalyses, and 3
reports of national
recommendations or
guidelines.

A search was conducted
of the entire PubMed
database (January 2000October 2008) using the
key words
“progesterone” and
“preterm”. A total of
240 abstracts were
reviewed to identify all
relevant clinical trials or
meta-analyses of
clinical trials evaluating
the effect of antenatal
maternal use of
progesterone on the risk
of preterm birth. A
bibliographic review
was then conducted of
the selected reports.

After the sample was
selected, relevant
pharmacologic data on
progesterone
formulation (type,
dose, route, side
effects) and pregnancy
outcome by risk group
under study was
abstracted. An analytic
approach was applied
to the synthesis of the
data from these reports
(i.e., analyzed observed
similarities and/or
differences without
conducting additional
meta-analyses). RR
and 95% CI for
pertinent outcomes
were obtained either
from the reports or,
when not available,
calculated form the
reported data.

The reviewed data
strongly suggests
that prophylactic
use of progesterone
leads to significant
reductions in the
measures of preterm
birth and low birth
weight.

Additional research is needed to clarify if
progesterone may benefit neonatal morbidity
and mortality. Additional research is also
needed in the areas of identifying risk
groups, and superior route of administration
and dose.
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Purpose

Sample

Design

Measurement

Results/Conclusion

To systematically
review the
effectiveness of
intramuscular (IM),
vaginal, or oral
progestogens for
preterm birth and
neonatal death
prevention.

The databases MEDLINE and
EMBASE for English
language articles published
from January 1966 to January
2013 were searched.
Controlled vocabulary terms
served as the foundation of the
search, complimented by
additional keyword phrases to
represent the myriad ways in
which progestogens and
preterm labor are referred to in
the clinical literature. The
references of the included
articles were also handsearched to identify studies.
Randomized controlled trials
with 20 or more women were
included in order to have
adequate power for statistical
analysis. All formulations and
drug delivery routes were
included. Analyses were
limited to only major
indications for progestogen
treatment that include prior
preterm births, preterm labor,
short cervix, and multiple
gestations. 27 randomized
trials were identified with data
for Bayesian meta-analysis.

A Bayesian
meta-analysis
was conducted
to provide
aggregate
estimates of
the
effectiveness
of
progestogen
treatment for
preventing
preterm birth
and reducing
neonatal
death.

The primary
outcomes extracted
from articles were
preterm birth [less
than 33 (singleton
with short cervix),
34 (multiples and
singleton with short
cervix), 35
(multiples), and 37
(singleton) weeks’
gestation] and
neonatal death.

Across all studies,
only vaginal and oral
routes were effective
at reducing preterm
births. However,
when analyses were
limited to only single
births, all routes were
effective in reducing
preterm birth. Only
IM progestogen was
effective at reducing
neonatal deaths.
Vaginal progestogen
was effective in
reducing neonatal
deaths when limited
to singleton births.

Recommendations
All progestogen routes reduce preterm
births but not neonatal deaths. The
overall strength of the evidence was
insufficient or low supporting the need
for future studies that directly compare
progestogen delivery routes.

